Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index; 26 of the 61 sources its claims cite were checked for support.

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Open access

Abstract

Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this program represent a unique opportunity to analyze the real-world practice of PAT. Aims: This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers. For the patients, it also investigated the relationship between antidepressant effects and six measures of acute drug effects. Methods: We compared data on acute psychedelic drug effects between 28 PAT patients with data from 28 healthy participants who participated in a randomized, double-blind crossover trial. All participants received varying doses of psilocybin and LSD. Subjective effects were assessed on an hourly basis during the acute drug effects, and the Mystical Experience Questionnaire (MEQ) was completed retrospectively. For patients, depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Results: Ratings of overall drug effect and mystical experience were similar across groups. Compared with healthy controls, patients reported lower ratings of ego dissolution. Patients showed a significant decrease in MADRS scores, and the greatest predictor of antidepressant outcome was relaxation during the PAT session. We did not observe a relationship between mystical-type experiences and antidepressant effects. Most patients experienced mild adverse effects which resolved within 48 h. Conclusion: PAT reduced depressive symptoms in this heterogeneous patient group. Patients may experience more challenging psychedelic effects and reduced ego dissolution. Hourly assessment of drug effects may predict clinical outcomes better than retrospectively assessed mystical experiences, and the impact of relaxation during PAT should be investigated further. © The Author(s) 2024.

Overview

CoChat Summary

## TL;DR

In this naturalistic Swiss PAT study, patients receiving LSD or psilocybin showed a significant reduction in depressive symptoms, and the strongest predictor of immediate antidepressant response was relaxation during the session. Compared with healthy volunteers, patients reported less ego dissolution, while retrospective mystical-experience scores were not associated with antidepressant effects.

## Key findings

  • In 21 patients with treatment-resistant depression, mean MADRS score was 20.9 at baseline and fell by 29% (6.2 points) immediately after PAT; the improvement remained significant at follow-up about 7.7 days later.
  • Across 55 treatment sessions in 28 patients, subjective “any drug effect” ratings increased with dose (F(5, 30) = 6.884, p < 0.001).
  • Compared with 28 healthy participants, patients had significantly lower ego dissolution ratings (β = −183.50, SE = 36.01, p < 0.001); overall drug effect and good drug effect were not significantly different, and bad drug effect was higher but not statistically significant (p = 0.09).
  • For immediate antidepressant response, real-time acute effect ratings explained 28% of the variance in MADRS improvement, while MEQ scores explained 4%; among the real-time ratings, relaxation was the only significant predictor (β = −0.04, SE = 0.01, p = 0.03).

## Methods

  • Naturalistic, open-label PAT data from 28 Swiss patients undergoing 55 sessions with LSD or psilocybin were compared with data from 28 healthy volunteers in a randomized, double-blind crossover trial.
  • Patients were mostly residents of Switzerland, average age 49, and 78.6% were taking psychiatric medications; 24/28 had treatment-resistant major depressive disorder and the rest had OCD, bipolar disorder, or social anxiety.
  • Acute effects were rated hourly in patients and at least hourly in healthy participants; analyses used linear mixed-effects models, with AUC for acute ratings and MADRS used to assess depressive symptoms.

## Limitations

  • The paper states that the patient data were heterogeneous, open-label, non-randomized, and uncontrolled, and that all patients were in psychotherapy before and after dosing, limiting causal inference.
  • Follow-up times were relatively short, the patient sample was relatively small and underpowered for some analyses, and some MADRS and MEQ data were missing.
  • The paper notes that some dose groups were extremely small, flexible dosing limited dose comparability, and the patient and healthy samples came from two different hospitals; these are evident limitations from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/02698811241278873

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Procedures and assessments in the patient group undergoing psychedelic-assisted therapy (PAT). PAT consisted of two preparatory consultations, one dosing session, and one follow-up consultation. Individual patients could repeat PAT at most once every 3 months. MADRS: Montgomery-Åsberg depression rating scale; MEQ: mystical experience questionnaire.
Figure 1. Procedures and assessments in the patient group undergoing psychedelic-assisted therapy (PAT). PAT consisted of two preparatory consultations, one dosing session, and one follow-up consultation. Individual patients could repeat PAT at most once every 3 months. MADRS: Montgomery-Åsberg depression rating scale; MEQ: mystical experience questionnaire.CC BY · PubMed Central
Figure 2. Therapy room at the Fribourg Network for Mental Health in which PAT sessions are conducted.
Figure 2. Therapy room at the Fribourg Network for Mental Health in which PAT sessions are conducted.CC BY · PubMed Central
Figure 3. Subjective effects of different doses of LSD and psilocybin in patients. Data are shown as mean ± SEM. N = 54 PAT sessions in 28 patients (100 µg LSD = 19, 150 µg LSD = 2, 200 µg LSD = 8, 15 mg psilocybin = 15, 20 mg psilocybin = 7, 25 mg psilocybin = 3). There was a significant dose–response effect for any drug effect (p < 0.001). Other dose–response curves are shown for illustrative purposes.
Figure 3. Subjective effects of different doses of LSD and psilocybin in patients. Data are shown as mean ± SEM. N = 54 PAT sessions in 28 patients (100 µg LSD = 19, 150 µg LSD = 2, 200 µg LSD = 8, 15 mg psilocybin = 15, 20 mg psilocybin = 7, 25 mg psilocybin = 3). There was a significant dose–response effect for any drug effect (p < 0.001). Other dose–response curves are shown for illustrative purposes.CC BY · PubMed Central
Figure 4. Average real-time ratings of any drug effect, good drug effect, bad drug effect, and ego dissolution at different doses for healthy subjects and patients. Data are shown as mean ± SEM. N = 28 healthy subjects for all doses and 42 PAT sessions in 27 patients (100 µg LSD = 19, 200 µg LSD = 8, 15 mg psilocybin = 15). Overall, patients had lower ratings of ego dissolution (p < 0.001). The higher ratings of bad drug effects were not statistically significant (p = 0.09). There was also no significant difference in any drug effect or good drug effect.
Figure 4. Average real-time ratings of any drug effect, good drug effect, bad drug effect, and ego dissolution at different doses for healthy subjects and patients. Data are shown as mean ± SEM. N = 28 healthy subjects for all doses and 42 PAT sessions in 27 patients (100 µg LSD = 19, 200 µg LSD = 8, 15 mg psilocybin = 15). Overall, patients had lower ratings of ego dissolution (p < 0.001). The higher ratings of bad drug effects were not statistically significant (p = 0.09). There was also no significant difference in any drug effect or good drug effect.CC BY · PubMed Central
Figure 5. Average MEQ scores at different total doses for healthy subjects and patients. N = 28 healthy subjects for all doses and 26 PAT sessions in 19 patients (100 µg LSD = 12, 200 µg LSD = 9, 15 mg psilocybin = 5). There were no statistically significant differences between healthy subjects and patients.
Figure 5. Average MEQ scores at different total doses for healthy subjects and patients. N = 28 healthy subjects for all doses and 26 PAT sessions in 19 patients (100 µg LSD = 12, 200 µg LSD = 9, 15 mg psilocybin = 5). There were no statistically significant differences between healthy subjects and patients.CC BY · PubMed Central
Figure 6. Relationship between real-time ratings of drug effects and subsequent MEQ scores. Gray shading depicts the 95% confidence interval. Ego dissolution was the only significant predictor in a linear mixed model (p < 0.001). N = 153 dosing sessions in 53 subjects, corresponding statistics from mixed-effects models are found in Table S3. AUC: area under the curve; MEQ; mystical experience questionnaire.
Figure 6. Relationship between real-time ratings of drug effects and subsequent MEQ scores. Gray shading depicts the 95% confidence interval. Ego dissolution was the only significant predictor in a linear mixed model (p < 0.001). N = 153 dosing sessions in 53 subjects, corresponding statistics from mixed-effects models are found in Table S3. AUC: area under the curve; MEQ; mystical experience questionnaire.CC BY · PubMed Central
Figure 7. Patients showed significant reductions in MADRS scores after PAT treatment sessions (p < 0.001). Data are shown as mean (SEM). N = 41 PAT sessions in 21 patients at 8 h and 27 PAT sessions in 14 patients at 7.7 days. MADRS: Montgomery-Åsberg depression rating scale. ; MEQ: mystical experience questionnaire.
Figure 7. Patients showed significant reductions in MADRS scores after PAT treatment sessions (p < 0.001). Data are shown as mean (SEM). N = 41 PAT sessions in 21 patients at 8 h and 27 PAT sessions in 14 patients at 7.7 days. MADRS: Montgomery-Åsberg depression rating scale. ; MEQ: mystical experience questionnaire.CC BY · PubMed Central
Figure 8. Relationship between acute effects and improvement in depressive symptoms immediately after treatment. Relaxation was the only significant predictor (p = 0.03). N = 29 treatment sessions in 18 patients, corresponding statistics from the mixed-effects models are shown in Table S5. Gray shading depicts the 95% confidence interval. MADRS: Montgomery–Åsberg depression rating scale; AUC: area under the curve; MEQ: mystical experience questionnaire.
Figure 8. Relationship between acute effects and improvement in depressive symptoms immediately after treatment. Relaxation was the only significant predictor (p = 0.03). N = 29 treatment sessions in 18 patients, corresponding statistics from the mixed-effects models are shown in Table S5. Gray shading depicts the 95% confidence interval. MADRS: Montgomery–Åsberg depression rating scale; AUC: area under the curve; MEQ: mystical experience questionnaire.CC BY · PubMed Central
Figure 9. Impact of psychiatric medications on acute drug effects. Controlling for dose, we did not observe significant differences between patients on medication at the time of each PAT session (N = 22 patients, 37 sessions) and those not on medication (N = 7 patients, 17 sessions). Gray shading represents 95% confidence intervals. AUC: area under the curve; MEQ: mystical experience questionnaire.
Figure 9. Impact of psychiatric medications on acute drug effects. Controlling for dose, we did not observe significant differences between patients on medication at the time of each PAT session (N = 22 patients, 37 sessions) and those not on medication (N = 7 patients, 17 sessions). Gray shading represents 95% confidence intervals. AUC: area under the curve; MEQ: mystical experience questionnaire.CC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 0 Not valid · 22 Not checked · 75 Own results and interpretations

53 more claims

Create a free account to see all 117 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 45
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • ConsistentF(5, 30) = 6.884reported p < .001 · recomputed p < .001

    “F(5, 30) = 6.884, p < .001”

  • Consistentt(45.71) = 4.2reported p < .001 · recomputed p < .001

    “t(45.71) = 4.2, p < .001”

2 of 2

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Citations

Cites

Show all 83 references

Research works printed but not linked: 1

  1. Haden M, 2019, Manual for Psychedelic Guides

Cited by

See all 20

Metadata

Authors
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G.
Affiliations
  • University of Freiburg (DE)
  • Saarland University (DE)
  • University of Basel (CH)
Corresponding author
Hasler, Gregor
Venue
Journal of Psychopharmacology
Published
2024-09-20
Volume
38
Issue
10
Pages
873-886
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4402680012
Cited by
20
References
83
Citations by year
2026: 10 · 2025: 9 · 2024: 1
FWCI
9.97
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psychedelic therapy, psilocybin, lysergic acid diethylamide, depression, antidepressant response, subjective drug effects, relaxation, ego dissolution, mystical experience, adverse effects, real-world practice
MeSH terms
Adult, Antidepressive Agents, Depression, Double-Blind Method, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, Mysticism, Psilocybin, Psychiatric Status Rating Scales, Relaxation, Switzerland, Treatment Outcome, Cross-Over Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. https://app.cochat.ai/papers/10.1177/02698811241278873
The paper
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024). Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241278873

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.